Compare Sterling Biotech with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs STRIDES PHARMA SCIENCE - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH STRIDES PHARMA SCIENCE STERLING BIOTECH/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x -0.4 15.1 - View Chart
P/BV x 0.0 0.9 1.6% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 STERLING BIOTECH   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
STRIDES PHARMA SCIENCE
Mar-18
STERLING BIOTECH/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs111,147 0.9%   
Low Rs3642 0.5%   
Sales per share (Unadj.) Rs26.8317.2 8.4%  
Earnings per share (Unadj.) Rs-15.07.8 -190.7%  
Cash flow per share (Unadj.) Rs-5.525.1 -21.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs54.9274.3 20.0%  
Shares outstanding (eoy) m267.8789.50 299.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 9.2%   
Avg P/E ratio x-0.5114.0 -0.4%  
P/CF ratio (eoy) x-1.335.7 -3.6%  
Price / Book Value ratio x0.13.3 3.9%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m1,86280,058 2.3%   
No. of employees `0001.42.5 54.0%   
Total wages/salary Rs m5474,341 12.6%   
Avg. sales/employee Rs Th5,303.311,325.8 46.8%   
Avg. wages/employee Rs Th403.81,731.4 23.3%   
Avg. net profit/employee Rs Th-2,959.0280.1 -1,056.6%   
INCOME DATA
Net Sales Rs m7,18128,394 25.3%  
Other income Rs m43941 4.5%   
Total revenues Rs m7,22329,334 24.6%   
Gross profit Rs m9473,965 23.9%  
Depreciation Rs m2,5431,540 165.1%   
Interest Rs m4,3771,962 223.0%   
Profit before tax Rs m-5,9311,403 -422.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m-1,92497 -1,977.7%   
Profit after tax Rs m-4,007702 -570.6%  
Gross profit margin %13.214.0 94.4%  
Effective tax rate %32.46.9 467.9%   
Net profit margin %-55.82.5 -2,256.4%  
BALANCE SHEET DATA
Current assets Rs m14,33524,836 57.7%   
Current liabilities Rs m49,80918,993 262.3%   
Net working cap to sales %-494.020.6 -2,400.7%  
Current ratio x0.31.3 22.0%  
Inventory Days Days40371 568.4%  
Debtors Days Days171113 150.5%  
Net fixed assets Rs m55,43234,289 161.7%   
Share capital Rs m268895 29.9%   
"Free" reserves Rs m13,93523,651 58.9%   
Net worth Rs m14,70124,546 59.9%   
Long term debt Rs m9,47815,513 61.1%   
Total assets Rs m73,98865,437 113.1%  
Interest coverage x-0.41.7 -20.7%   
Debt to equity ratio x0.60.6 102.0%  
Sales to assets ratio x0.10.4 22.4%   
Return on assets %0.54.1 12.3%  
Return on equity %-27.32.9 -952.8%  
Return on capital %-6.46.9 -93.2%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86015,697 11.8%   
Fx outflow Rs m25735 3.4%   
Net fx Rs m1,83514,962 12.3%   
CASH FLOW
From Operations Rs m1,7191,871 91.9%  
From Investments Rs m-3,1485,826 -54.0%  
From Financial Activity Rs m1,426-10,157 -14.0%  
Net Cashflow Rs m-3-2,615 0.1%  

Share Holding

Indian Promoters % 33.9 27.7 122.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 37.8 -  
FIIs % 9.9 8.6 115.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 25.9 151.7%  
Shareholders   21,482 56,241 38.2%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS